Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


American Heart Association Research, In Brief

Executive Summary

Outcomes Study Resuscitates Natrecor

You may also be interested in...

Outcomes Data For Pfizer's Inspra Could Give Heart Failure Drug A Jumpstart

Pfizer's Inspra has been a commercial flop, but now a post-marketing study has shown positive results in a broader patient population

FDA Approval Shouldn’t Be Based On Surrogate Endpoints – Natrecor Article

The ongoing debate surrounding the safety of Scios' congestive heart failure therapy Natrecor (nesiritide) suggests that FDA should not approve drugs based only on surrogate endpoints, an article published in the July/August 2006 issue of Health Affairs argues

Scios Natrecor Outcomes Study Is Expected To Begin Enrollment In 2007

The Johnson & Johnson subsidiary will begin enrollment more than a year after an independent panel recommended the study.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts